Toggle Main Menu Toggle Search

Open Access padlockePrints

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

Lookup NU author(s): Noel Monks, Professor Nicola Curtin, Emeritus Professor Herbie Newell

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in colorectal tumour cell-lines. Depletion of intracellular GSH using buthionine sulfoximine (BSO) resulted in only a modest potentiation of ZD2767P + CPG2 activity and hence BSO is unlikely to markedly enhance the activity of this ADEPT treatment. (C) 2000 Cancer Research Campaign.


Publication metadata

Author(s): Monks, N., Calvete, J., Curtin, N.J., Blakey, D., East, S., Newell, D.R.

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2000

Volume: 83

Issue: 2

Pages: 267-269

Print publication date: 01/01/2000

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

URL: http://dx.doi.org/10.1054/bjoc.2000.1240

DOI: 10.1054/bjoc.2000.1240

PubMed id: 10901381


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share